{
 "awd_id": "0078716",
 "agcy_id": "NSF",
 "tran_type": "Grant",
 "awd_istr_txt": "Standard Grant",
 "awd_titl_txt": "SBIR Phase II: Clinical-Scale Suspension Bioreactor for Primary Hematopoietic Culture",
 "cfda_num": "47.084",
 "org_code": "15030000",
 "po_phone": null,
 "po_email": "",
 "po_sign_block_name": "George B. Vermont",
 "awd_eff_date": "2000-12-01",
 "awd_exp_date": "2002-02-28",
 "tot_intn_awd_amt": 400000.0,
 "awd_amount": 400000.0,
 "awd_min_amd_letter_date": "2000-07-24",
 "awd_max_amd_letter_date": "2000-07-24",
 "awd_abstract_narration": "This Small Business Innovation Research Phase II project describes the\r\ndevelopment of a disposable, highly  efficient suspension bioreactor for \r\nprimary hematopoietic (blood cell-forming) cell culture. The unique \r\nchallenges (heterogeneous nature, donor variability, and shear-sensitivity)\r\nof these cultures render traditional flask or suspension cultures unable to \r\neconomically and consistently produce large quantities of cells. In Phase I, \r\nthe feasibility and characteristics of a disposable suspension bioreactor was \r\ndemonstrated. In Phase II, a scaled-up prototype of a large, agitated \r\ndisposable bioreactor designed for clinical use (stem cell transplantation)\r\n will be constructed, characterized, and tested for reliability and durability. \r\nGas and mass transfer correlations established in Phase I will be verified \r\nand extended. The use of medium optical density as a surrogate measure \r\nfor cell density will be investigated.\r\n\r\nThe final product will be a system that combines the simple, disposable nature \r\nof flask culture with the control and monitoring capabilities of a suspension \r\nbioreactor. The resulting system will enable the cost-effective production of \r\nlarge numbers of primary hematopoietic cells and will improve the effectiveness\r\nand decrease the cost of medical procedures in the fields of transplantation, \r\nimmunotherapy, and gene therapy.\r\n",
 "awd_arra_amount": 0.0,
 "dir_abbr": "TIP",
 "org_dir_long_name": "Directorate for Technology, Innovation, and Partnerships",
 "div_abbr": "TI",
 "org_div_long_name": "Translational Impacts",
 "awd_agcy_code": "4900",
 "fund_agcy_code": "4900",
 "pi": [
  {
   "pi_role": "Principal Investigator",
   "pi_first_name": "Todd",
   "pi_last_name": "McAdams",
   "pi_mid_init": "A",
   "pi_sufx_name": "",
   "pi_full_name": "Todd A McAdams",
   "pi_email_addr": "lcfarrar@resodyn.com",
   "nsf_id": "000416172",
   "pi_start_date": "2000-07-24",
   "pi_end_date": null
  }
 ],
 "inst": {
  "inst_name": "Tissue Therapeutics",
  "inst_street_address": "2143 Sheridan Road",
  "inst_street_address_2": "",
  "inst_city_name": "Evanston",
  "inst_state_code": "IL",
  "inst_state_name": "Illinois",
  "inst_phone_num": "8474674559",
  "inst_zip_code": "602083120",
  "inst_country_name": "United States",
  "cong_dist_code": "09",
  "st_cong_dist_code": "IL09",
  "org_lgl_bus_name": null,
  "org_prnt_uei_num": null,
  "org_uei_num": null
 },
 "perf_inst": {
  "perf_inst_name": "Tissue Therapeutics",
  "perf_str_addr": "2143 Sheridan Road",
  "perf_city_name": "Evanston",
  "perf_st_code": "IL",
  "perf_st_name": "Illinois",
  "perf_zip_code": "602083120",
  "perf_ctry_code": "US",
  "perf_cong_dist": "09",
  "perf_st_cong_dist": "IL09",
  "perf_ctry_name": "",
  "perf_ctry_flag": "1"
 },
 "pgm_ele": [
  {
   "pgm_ele_code": "537300",
   "pgm_ele_name": "SBIR Phase II"
  }
 ],
 "pgm_ref": [
  {
   "pgm_ref_code": "1491",
   "pgm_ref_txt": "BIOTECH, BIOCHEM & BIOMASS ENG"
  },
  {
   "pgm_ref_code": "9181",
   "pgm_ref_txt": "BIOPROCESSING/BIOMOLECULAR MATERIALS"
  },
  {
   "pgm_ref_code": "BIOT",
   "pgm_ref_txt": "BIOTECHNOLOGY"
  }
 ],
 "app_fund": [
  {
   "app_code": "0100",
   "app_name": "NSF RESEARCH & RELATED ACTIVIT",
   "app_symb_id": "490100",
   "fund_code": "app-0100",
   "fund_name": "",
   "fund_symb_id": ""
  }
 ],
 "oblg_fy": [
  {
   "fund_oblg_fiscal_yr": 2000,
   "fund_oblg_amt": 180000.0
  }
 ],
 "por": null
}